{"id":"NCT01285609","sponsor":"Bristol-Myers Squibb","briefTitle":"Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin","officialTitle":"Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab in Addition to Paclitaxel and Carboplatin Versus Placebo in Addition to Paclitaxel and Carboplatin in Subjects With Stage IV/Recurrent Non Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-01-16","primaryCompletion":"2015-06-09","completion":"2017-08-22","firstPosted":"2011-01-28","resultsPosted":"2016-06-23","lastUpdate":"2020-06-18"},"enrollment":1289,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Lung Cancer - Non Small Cell Squamous"],"interventions":[{"type":"DRUG","name":"Ipilimumab","otherNames":["BMS-734016"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Paclitaxel","otherNames":["Taxol®"]},{"type":"DRUG","name":"Carboplatin","otherNames":["Paraplatin®"]}],"arms":[{"label":"Ipilimumab + Paclitaxel and Carboplatin","type":"EXPERIMENTAL"},{"label":"Placebo + Paclitaxel and Carboplatin","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the study is to determine whether Ipilimumab plus Paclitaxel and Carboplatin will extend the lives of patients with squamous only non small cell lung cancer more than placebo plus Paclitaxel and Carboplatin.","primaryOutcome":{"measure":"Overall Survival (OS) in Participants Who Received at Least One Dose of Blinded Study Therapy at Primary Endpoint","timeFrame":"Randomization until 518 deaths were observed in randomized participants treated with at least one dose of blinded study therapy and 705 deaths were observed in all randomized participants, up to June 2015 (approximately 48 months post study start)","effectByArm":[{"arm":"Ipilimumab With Paclitaxel/Carboplatin","deltaMin":13.37,"sd":null},{"arm":"Placebo With Paclitaxel/Carboplatin","deltaMin":12.42,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.2517"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":290,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","China","Colombia","Czechia","Denmark","France","Germany","Hong Kong","Hungary","Ireland","Israel","Italy","Japan","Mexico","Netherlands","Peru","Poland","Portugal","Romania","Russia","Singapore","South Africa","South Korea","Spain","Sweden","Switzerland","Taiwan","Thailand","United Kingdom"]},"refs":{"pmids":[],"seeAlso":["http://bms.com/studyconnect/Pages/home.aspx","http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx"]},"adverseEventsSummary":{"seriousAny":{"events":300,"n":475},"commonTop":["Alopecia","Anaemia","Nausea","Fatigue","Decreased appetite"]}}